Hongyan Li1, Huayi Lu2, Wanli Cui1, Yufan Huang1, Xuefei Jin1. 1. Jilin Key Laboratory of Urologic Oncology, Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. 2. The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Abstract
BACKGROUND: Muscle-invasive bladder cancer (MIBC) patients are subject to unfavorable treatment options and a high recurrence rate. The status of TP53 mutations played an essential role in the progression and the prognosis of MIBC. The present study proposed to investigate the association between TP53 mutations and immunophenotype in MIBC. RESULTS: We established an immune prognostic model (IPM) ground on the immune-associated genes derived from variation analysis between wild-type TP53 and mutated TP53 TCGA-MIBC patients, and validated in another cohort from GEO database. Based on IPM, we divided MIBC patients into low and high risk subgroups. The high risk MIBC patients had higher proportions of macrophages M1, and lower proportions of T cells regulatory (Tregs) and activated dendritic cells than the low risk MIBC patients. Moreover, the expression of immune checkpoints genes (PD1, CTLA4, LAG3, HAVCR2 and TIGIT) was higher in the high risk patients than the low risk patients. In clinical application, IPM exhibited better survival prediction than conventional clinical characteristics. CONCLUSIONS: Our investigation presented practical prognostic significance for MIBC patients and displayed the overarching landscape of the immune response in the MIBC microenvironment. METHODS: Data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) analysis between the TP53 mutated and wild-type MIBC patients was conducted. The CIBERSORT algorithm was performed to evaluate the proportion of immune cell types. Gene expression profiles from the TCGA and GEO were used as training and testing cohorts to build and validate an immune-related prognostic model (IPM). Genes in the IPM model were first screened by univariate Cox analysis, then filtered by the least absolute shrinkage and selection operator (LASSO) Cox regression. A nomogram was finally established and evaluated by combining both the IPM and other clinical factors.
BACKGROUND:Muscle-invasive bladder cancer (MIBC) patients are subject to unfavorable treatment options and a high recurrence rate. The status of TP53 mutations played an essential role in the progression and the prognosis of MIBC. The present study proposed to investigate the association between TP53 mutations and immunophenotype in MIBC. RESULTS: We established an immune prognostic model (IPM) ground on the immune-associated genes derived from variation analysis between wild-type TP53 and mutated TP53 TCGA-MIBCpatients, and validated in another cohort from GEO database. Based on IPM, we divided MIBCpatients into low and high risk subgroups. The high risk MIBCpatients had higher proportions of macrophages M1, and lower proportions of T cells regulatory (Tregs) and activated dendritic cells than the low risk MIBCpatients. Moreover, the expression of immune checkpoints genes (PD1, CTLA4, LAG3, HAVCR2 and TIGIT) was higher in the high risk patients than the low risk patients. In clinical application, IPM exhibited better survival prediction than conventional clinical characteristics. CONCLUSIONS: Our investigation presented practical prognostic significance for MIBCpatients and displayed the overarching landscape of the immune response in the MIBC microenvironment. METHODS: Data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) analysis between the TP53 mutated and wild-type MIBCpatients was conducted. The CIBERSORT algorithm was performed to evaluate the proportion of immune cell types. Gene expression profiles from the TCGA and GEO were used as training and testing cohorts to build and validate an immune-related prognostic model (IPM). Genes in the IPM model were first screened by univariate Cox analysis, then filtered by the least absolute shrinkage and selection operator (LASSO) Cox regression. A nomogram was finally established and evaluated by combining both the IPM and other clinical factors.
Authors: Carolin Pfannstiel; Pamela L Strissel; Katherine B Chiappinelli; Danijel Sikic; Sven Wach; Ralph M Wirtz; Adrian Wullweber; Helge Taubert; Johannes Breyer; Wolfgang Otto; Thomas Worst; Maximilian Burger; Bernd Wullich; Christian Bolenz; Nicole Fuhrich; Carol I Geppert; Veronika Weyerer; Robert Stoehr; Simone Bertz; Bastian Keck; Franziska Erlmeier; Philipp Erben; Arndt Hartmann; Reiner Strick; Markus Eckstein Journal: Cancer Immunol Res Date: 2019-04-15 Impact factor: 11.151
Authors: Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh Journal: Nat Methods Date: 2015-03-30 Impact factor: 28.547
Authors: Haven R Garber; Mao Zhang; Gheath Alatrash; Pariya Sukhumalchandra; Yihua Qiu; Haroon Jakher; Alexander A Perakis; Lisa Becker; Suk Young Yoo; Karen C Dwyer; Kevin Coombes; Amjad H Talukder; Lisa S St John; Vladimir Senyukov; Dean A Lee; Anna Sergeeva; Hong He; Qing Ma; Paul M Armistead; Jason Roszik; Elizabeth A Mittendorf; Jeffrey J Molldrem; David Hawke; Gregory Lizee; Steven M Kornblau Journal: Leukemia Date: 2016-08-30 Impact factor: 11.528